EUVIMEDEUVIMED entdecken
Crossref

Pan-immune-inflammation value as a novel biomarker for diabetic retinopathy severity

Yang Yang, Xiao-Si Chen, Wei-Chen Yuan, Han-Yu Wu, Yi-Yun Zeng, Xin-Yuan Zhang

International Journal of Ophthalmology · 18.12.2026 · 19 (12) · 2421-2429

DOI: 10.18240/ijo.2026.12.13 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Ophthalmology, erschienen am 18.12.2026. Verfasst von Yang Yang und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: To investigate the association between peripheral blood immune-inflammatory biomarkers (PBIBs), including the pan-immune-inflammation value (PIV), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI) of diabetic retinopathy (DR), to identify novel biomarkers and therapeutic targets. METHODS: This nested case-control study enrolled 228 patients with type 2 diabetes mellitus (T2DM). Based on the staging criteria outlined in the American Diabetes Association’s Position Statement on DR, patients were classified into three groups: diabetes without DR (diabetes mellitus, DM; n=75), non-proliferative DR (NPDR, n=80), and proliferative DR groups (PDR, n=73). Comprehensive clinical data, including fasting blood tests and biochemical profiles, were collected for all subjects. PIV and other PBIBs were calculated based on hematological parameters, specifically the absolute counts of neutrophils, platelets, and monocytes, along with their respective ratios to lymphocytes. Kendall’s tau-b analysis assessed the correlation between research indicators and DR severity, while Spearman analysis evaluated the associations with baseline characteristics. Ordinal logistic regression was used to evaluate the predictive performance of peripheral blood molecular markers for DR severity. RESULTS: The study included 75 patients in the DM group (41 males), aged 60.00y (interquartile range, IQR 56.00, 66.00), 80 patients in the NPDR group (44 males), aged 60.50y (IQR 57.00, 66.00), and 73 patients in the PDR group (43 males) aged 61.00y (IQR 56.50, 68.00). PBIBs, most notably PIV, showed significant intergroup differences and demonstrated positive correlations with the severity of DR (all P

Zitieren

APA

Yang, Y., Chen, X., Yuan, W., Wu, H., Zeng, Y., & Zhang, X. (2026). Pan-immune-inflammation value as a novel biomarker for diabetic retinopathy severity. International Journal of Ophthalmology, 19(12), 2421-2429. https://doi.org/10.18240/ijo.2026.12.13

Vancouver

Yang Y, Chen X, Yuan W, Wu H, Zeng Y, Zhang X. Pan-immune-inflammation value as a novel biomarker for diabetic retinopathy severity. International Journal of Ophthalmology. 2026;19(12):2421-2429. doi:10.18240/ijo.2026.12.13

BibTeX
@article{Yang2026,
  author = {Yang, Yang and Chen, Xiao-Si and Yuan, Wei-Chen and Wu, Han-Yu and Zeng, Yi-Yun and Zhang, Xin-Yuan},
  title = {Pan-immune-inflammation value as a novel biomarker for diabetic retinopathy severity},
  journal = {International Journal of Ophthalmology},
  year = {2026},
  volume = {19},
  number = {12},
  pages = {2421--2429},
  doi = {10.18240/ijo.2026.12.13}
}
Kostenlos starten →